Publications by authors named "R F Samigullina"
Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation.
BMC Rheumatol
January 2025
Background: The real-world effectiveness of intravenous (IV) belimumab in treating systemic lupus erythematosus (SLE) has been demonstrated in various countries through the OBSErve (evaluation Of use of Belimumab in clinical practice SEttings) program. Here we describe the clinical effectiveness of IV belimumab for treating SLE in real-world clinical practice in the Russian Federation.
Methods: In the retrospective, observational OBSErve Russia study (GSK Study 215349), eligible physicians enrolled adults with SLE receiving IV belimumab as part of their standard care.
Article Synopsis
- Netakimab has shown effective results in controlled trials for treating ankylosing spondylitis (AS), and this study investigates its efficacy and safety in everyday clinical settings over a year.
- The observational study included 137 patients from 23 centers in Russia, focusing on retention rates and the impact of netakimab therapy at multiple time points during the year.
- Findings revealed that 90.4% of patients continued treatment after one year, and significant improvements were observed in disease activity scores, with only a small percentage experiencing adverse effects.
The aim of the study was to evaluate the effectiveness of UPA in RA patients in real clinical practice after 3 and 6 months of therapy. The study included 63 RA patients with high activity of the disease. Activity was assessed according to the DAS28(ESR), DAS28(CRP), SDAI, CDAI; functional ability to HAQ; quality of life to the EQ-5D; disease activity according to the patient's RAPID-3 index; the level of depression and anxiety to the HADS scale.
View Article and Find Full Text PDFUnlabelled: A retrospective cohort study determined the high incidence of recurrent fractures in osteoporotic patients with high fracture risk during the observation. The strategy of starting treatment with more potent regimens (zoledronic acid, denosumab and/or teriparatide) seems to have the best secondary fracture prevention efficacy.
Objective: This paper describes the various medical therapy regimens prescribed to osteoporotic patients with high fracture risk and the result of treatment.